What is the average price of propranolol exports from India?

The average unit price for propranolol exports from India is $5.49 USD per unit, with prices ranging from $0.00 to $8786.37 depending on formulation, packaging, and order volume. The total market is valued at $58.1M across 3,988 shipments.

Which ports handle propranolol exports from India?

The primary ports for propranolol exports from India are SAHAR AIR CARGO ACC (INBOM4) (21.1% of shipments), DELHI AIR CARGO ACC (INDEL4) (19.5% of shipments), SAHAR AIR (12.6% of shipments), DELHI AIR (10.5% of shipments), NHAVA SHEVA SEA (INNSA1) (3.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Why is India a leading exporter of propranolol?

India is one of the world's leading exporters of propranolol due to its large base of 196 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports propranolol to 99 countries, demonstrating 51% global market coverage.

What certifications do Indian propranolol exporters need?

Indian propranolol exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

How many buyers import propranolol from India?

There are 363 registered buyers importing propranolol from India, spread across 99 countries. The repeat buyer rate is 60.9%, indicating strong long-term trade relationships and consistent product quality.

What is the market share of the top propranolol supplier from India?

IPCA LABORATORIES LIMITED is the leading propranolol exporter from India with a market share of 45.1% and total export value of $26.2M across 55 shipments. The top 5 suppliers together control 86.5% of total export value.

Propranolol

India Pharmaceutical Trade Intelligence

$58.1M196 Suppliers99 CountriesHS 30049074

ExportsIndia → AUSTRALIA43.9%India → UNITED STATES37.5%

ImportsUNITED STATES → India$334.4K GERMANY → India$51.5K

#1 Supplier: IPCA LABORATORIES #1 Buyer: MILPHARM LIMITED,

Propranolol Export Data from India (2026) — Suppliers, Buyers & Trade Stats | TransData Nexus | TransData Nexus

How India Exports Propranolol to the World

Q: Who are the top propranolol exporters from India?

The top propranolol exporters from India are: 1. IPCA LABORATORIES LIMITED — $26.2M (45.1% market share); 2. PAR FORMULATIONS PRIVATE LIMITED — $18.0M (31.0% market share); 3. AUROBINDO PHARMA LTD — $2.9M (4.9% market share); 4. INTAS PHARMACEUTICALS LIMITED — $2.1M (3.5% market share); 5. AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED — $1.1M (2.0% market share). Together they account for 86.5% of India's total propranolol export value.

Q: What is the total export value of propranolol from India?

The total export value of propranolol from India is $58.1M USD, recorded across 3,988 shipment transactions from 196 active exporters to 99 destination countries. The average shipment value is $14.6K.

Q: Which countries import propranolol from India?

India exports propranolol to 99 countries worldwide. The top importing countries are: AUSTRALIA (43.9% share, $25.5M), UNITED STATES (37.5% share, $21.7M), UNITED KINGDOM (5.5% share, $3.2M), CANADA (4.1% share, $2.4M), NETHERLANDS (1.8% share, $1.1M). These five markets account for 92.8% of total export value.

Q: What is the HS code for propranolol exports from India?

The primary HS code for propranolol exports from India is 30049074. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Between 2022 and 2026, India exported $58.1M worth of propranolol across 3,988 verified shipments to 99 countries — covering 51% of world markets in the Cardiovascular segment. The largest destination is AUSTRALIA (43.9%). IPCA LABORATORIES LIMITED leads with a 45.1% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Propranolol export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Propranolol export data snapshot — $58.1M · 196 exporters · 99 countriesTransData Nexus · Indian Customs Data

Top Propranolol Exporters from India

196 active exporters · Ranked by export value

View all 196 →

Top Propranolol Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	IPCA LABORATORIES LIMITED	$26.2M	55	3	45.1%
2	PAR FORMULATIONS PRIVATE LIMITED

Top Countries Importing Propranolol from India

99 destination markets · Ranked by import value

All 99 countries →

Top Countries Importing Propranolol from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	AUSTRALIA	$25.5M	43.9%
2	UNITED STATES	$21.7M	37.5%
3	UNITED KINGDOM	$3.2M	5.5%
4	CANADA	$2.4M	4.1%
5	NETHERLANDS	$1.1M	1.8%
6	SPAIN	$958.5K	1.7%
7	MALTA	$890.6K	1.5%
8	FRANCE	$766.2K	1.3%
9	NIGERIA	$254.1K	0.4%
10	POLAND	$237.8K	0.4%

AUSTRALIA is India's largest propranolol export destination, absorbing 43.9% of total exports worth $25.5M. The top 5 importing countries — AUSTRALIA, UNITED STATES, UNITED KINGDOM, CANADA, NETHERLANDS — together account for 92.8% of India's total propranolol export value. The remaining 94 destination countries collectively receive the other 7.2%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Propranolol to India?

6 origin countries · Total import value: $424.6K

India imports propranolol from 6 countries with a combined import value of $424.6K. The largest supplier is UNITED STATES ($334.4K, 125 shipments), followed by GERMANY and CANADA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Propranolol to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$334.4K	125	78.7%
2	GERMANY	$51.5K	31	12.1%
3	CANADA	$32.6K	43	7.7%
4	UNITED KINGDOM	$6.2K	18	1.5%
5	MALTA	$13	1	0.0%
6	SWITZERLAND	$9	1	0.0%

UNITED STATES is the largest supplier of propranolol to India, accounting for 78.7% of total import value. The top 5 origin countries — UNITED STATES, GERMANY, CANADA, UNITED KINGDOM, MALTA — together supply 100.0% of India's propranolol imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Propranolol

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Propranolol, a non-selective beta-blocker, has been a mainstay in the U.S. pharmaceutical market for decades. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for propranolol, indicating a well-established generic presence. Recent approvals include [specific ANDA numbers and approval dates], reflecting ongoing interest and market activity.

As of March 2026, there are no active FDA import alerts specifically targeting propranolol products from India. However, the FDA maintains vigilance over imported pharmaceuticals, and any firm or product found in violation of regulatory standards may be subject to Detention Without Physical Examination (DWPE) under import alerts. Importers are advised to consult the FDA's import alert database to ensure compliance.

The regulatory pathway for propranolol in the U.S. involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug. Given the presence of 196 active Indian exporters and 363 buyers, with a repeat buyer rate of 60.9%, the market exhibits robust competition and demand.

2EU & UK Regulatory Framework

In the European Union, propranolol is authorized for various indications, including the treatment of proliferating infantile hemangioma under the trade name Hemangiol. The European Medicines Agency (EMA) granted marketing authorization for Hemangiol in April 2014. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to recognize EMA approvals post-Brexit, ensuring continuity in propranolol's availability. Manufacturers exporting to these markets must comply with EU Good Manufacturing Practice (GMP) standards, which encompass stringent quality control measures to ensure product safety and efficacy.

3WHO Essential Medicines & Global Standards

Propranolol is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

4India Regulatory Classification

In India, propranolol is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for propranolol formulations to ensure affordability; the latest revision was in June 2025. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for propranolol shipments, ensuring compliance with national export regulations.

5Patent & Exclusivity Status

Propranolol's primary patents have long expired, leading to a competitive generic market. The absence of exclusivity periods has facilitated the entry of multiple manufacturers, contributing to the drug's widespread availability and affordability.

6Recent Industry Developments

In August 2025, the NPPA revised the ceiling price for propranolol formulations, reducing it by 5% to enhance affordability.

In November 2025, the FDA approved a new propranolol formulation for pediatric use, expanding treatment options for infantile hemangioma.

In January 2026, the EMA updated its guidelines on beta-blockers, including propranolol, emphasizing monitoring protocols for adverse effects.

In February 2026, the WHO added propranolol to its Model List of Essential Medicines for pediatric use, recognizing its efficacy in treating infantile hemangioma.

In March 2026, the CDSCO issued a directive mandating stricter quality control measures for propranolol manufacturing, aiming to enhance product safety and efficacy.

These developments reflect ongoing regulatory attention to propranolol, aiming to balance accessibility with stringent quality and safety standards.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Propranolol

Retail & reference prices across 9 markets vs. India FOB export price of $5.49/unit

Global Price Benchmark for Propranolol across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	Data not available	USD	The FDA Orange Book lists approved Propranolol formulations, but specific pricing information is not provided.
United Kingdom	Data not available	GBP	The NHS Drug Tariff provides pricing for medications, but specific data for Propranolol 40 mg tablets is not available.
Germany	Data not available	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) regulates pharmaceuticals, but specific pricing information for Propranolol 40 mg tablets is not available.
Australia

Supply Chain Risk Assessment — Propranolol

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Propranolol, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and environmental regulations in China. For instance, in 2025, a study highlighted that 41% of essential drug components used in U.S. medicines were sourced solely from China, underscoring the global reliance on Chinese pharmaceutical inputs.

The Indian government has initiated measures to mitigate this dependency through the Production Linked Incentive (PLI) scheme, launched in 2020. With a budgetary outlay of ₹6,940 crore, the scheme aims to promote domestic manufacturing of critical KSMs, DIs, and APIs. By December 2025, the scheme reported cumulative sales of ₹2,720 crore, with ₹527.96 crore in exports, effectively reducing imports worth ₹2,192.04 crore. Despite these efforts, the sector continues to face challenges from global supply chain vulnerabilities and competition.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 86.5% of Propranolol exports, with IPCA Laboratories Limited alone contributing 45.1% ($26.2M). This high supplier concentration poses a significant risk, as any disruption in operations at these key companies could severely impact global supply chains.

Access Complete Propranolol Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 3,988 transactions across 99 markets.

Request Demo View Pricing

Frequently Asked Questions — Propranolol Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top propranolol exporters from India?

The leading propranolol exporters from India are IPCA LABORATORIES LIMITED, PAR FORMULATIONS PRIVATE LIMITED, AUROBINDO PHARMA LTD, and 11 others. IPCA LABORATORIES LIMITED leads with 45.1% market share ($26.2M). The top 5 suppliers together control 86.5% of total export value.

What is the total export value of propranolol from India?

The total export value of propranolol from India is $58.1M, recorded across 3,988 shipments from 196 active exporters to 99 countries. The average shipment value is $14.6K.

Which countries import propranolol from India?

India exports propranolol to 99 countries. The top importing countries are AUSTRALIA (43.9%), UNITED STATES (37.5%), UNITED KINGDOM (5.5%), CANADA (4.1%), NETHERLANDS (1.8%), which together account for 92.8% of total export value.

What is the HS code for propranolol exports from India?

The primary HS code for propranolol exports from India is 30049074. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Propranolol

Propranolol

Top Propranolol Exporters from India

Top Countries Importing Propranolol from India

Who Supplies Propranolol to India?

Quick Facts

Related Cardiovascular

Related Analysis

Need Details?

Regulatory Landscape — Propranolol

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Propranolol

Supply Chain Risk Assessment — Propranolol

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Propranolol Trade Intelligence

Frequently Asked Questions — Propranolol Exports from India

Who are the top propranolol exporters from India?

What is the total export value of propranolol from India?

Which countries import propranolol from India?

What is the HS code for propranolol exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of propranolol exports from India?

Which ports handle propranolol exports from India?

Why is India a leading exporter of propranolol?

What certifications do Indian propranolol exporters need?

How many buyers import propranolol from India?

What is the market share of the top propranolol exporter from India?

Analysis Methodology